Cathepsin B is a cysteine protease that is primarily found in the lysosomes of normal cells, but it is secreted or associated with the plasma membrane of many transformed cells. It is found in all animals and other organisms, and performs a key role in cellular protein turnover. The cathepsin family includes serine proteases, aspartic proteases, and cysteine proteases. The aspartyl protease class is composed of cathepsins D and E. The cysteine protease class comprises of cathepsins B, L, H, K, S, and O. Currently, there are no approved cathepsin inhibitors in the market, however research is underway for the development of novel cathepsin inhibitors for treatment of various conditions such as cancer, traumatic brain injury, Ebola infection, and others.
Anti-cathepsin B is also used in screening kits for diagnostic purposes. Antibodies of cathepsin B are used that recognizes an epitope on the heavy chain of mature Cathepsin B and therefore detects both mature and pro Cathepsin B. The anti-cathepsin B antibodies are used for ELISA, western blotting, flow cytometry and other screening purposes. It can be used to screen diseases like demyelination, emphysema, rheumatoid arthritis, and neoplastic infiltration.
Anti-cathepsin B Market - Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic has significantly augmented demand of anti-cathepsin B market. The spread of coronavirus is positively impacted the anti-cathepsin B market as the antibodies are expected to potential cure for COVID-19. For instance, according to data published in the Journal of Clinical Medicine Research on 5th May 2020, acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin II receptor in different tissues of the body, especially in the mouth cavity and the tongue and the skin. Therefore, it needs the serine protease, transmembrane serine protease 2 (TMPRSS2) for cell entry. Cathepsin L/B (CTSL/CTSB) plays an important role in a second pathway, the endosomal pathway. Hence, anti-cathepsin B treatment may provide potential solutions for coronavirus treatment.
The anti-cathepsin B market is estimated to be valued at US$ 166.52 million in 2020 and is expected to exhibit a CAGR of 2.8 % during the forecast period (2020-2027).
Figure 1: Anti-cathepsin B Market Share (%) Analysis, By Type, 2020
The Increasing Prevalence of Diseases Treated With Anti-Cathepsin B, and Research and Development Activities Are Expected To Drive Growth of the Anti-Cathepsin B Market
Anti-cathepsin B is expected to be useful for treating other conditions such as cancer, traumatic brain injury, Ebola infection, fertility problems, and others. Therefore, the increasing prevalence of such diseases is expected to boost the anti-cathepsin B market growth over the forecast period. For instance, according to the GLOBOCAN 2018 database, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. As per the same source, one in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.
Furthermore, the anti-cathepsin B market is expected to witness significant growth in the near future owing to the increasing research and development activities. For instance, the report titled “Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate” published in Frontiers Neurology Journal in September 2015, showed supporting evidence for cathepsin B, a cysteine protease, as a potentially important drug target for traumatic brain injury (TBI). Cathepsin B expression is greatly up-regulated in TBI animal models, as well as in trauma patients.
Chemical inhibitors of cathepsin B are effective in improving deficits in TBI and related injuries including ischemia, cerebral bleeding, cerebral aneurysm, edema, pain, infection, rheumatoid arthritis, epilepsy, Huntington’s disease, multiple sclerosis, and Alzheimer’s disease. The inhibitor E64d is unique among cathepsin B inhibitors and is the only compound to have demonstrated oral efficacy in a TBI model and prior safe use in human and is an effective tool compound for preclinical testing and clinical compound development.
Anti-cathepsin B Market Report Coverage
||Market Size in 2019:
||US$ 166.52 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 208.19 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel and rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Product Type: Primary Antibodies, Proteins and Peptides, Lysates.
- By Application: Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, Others.
- By Technique: Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, Others.
- By End User: Pharmaceutical Companies, Academic and Research Institutes.
Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc.
- The increasing prevalence of disorders treated with anti-cathepsin B
- The increasing number of research and developments activities
Anti-cathepsin B Market – Regional Analysis
The North America anti-cathepsin B market is expected to hold a dominant position in the global cathepsin inhibitors market owing to the high prevalence of conditions such as cancer and traumatic brain injury which will increase demand for novel treatment approaches such as anti-cathepsin B in this region. For instance, according to data published by the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer will be diagnosed in the U.S. and around 609,640 people will die from the disease.
Furthermore, a wide range of anti-cathepsin B products offered by key players is expected to accelerate the growth of the anti-cathepsin B market in the near future. For instance, Merck KGaA a Germany-based pharmaceutical, chemical and life sciences products company offers various anti-cathepsin products under the Calbiochem brand. The Cathepsin B Inhibitor II controls the biological activity of Cathepsin B. This small molecule/inhibitor is primarily used for Protease Inhibitors Techniques. The company also offers diagnostic products such as Cathepsin B Inhibitor Screening Kit which is a simple assay for screening potential inhibitors of CTSB (cathepsin B).
Figure 2: Anti-cathepsin B Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Anti-cathepsin B Market - Competitive Landscape
Key players operating in the anti-cathepsin B market are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc